The Uromigos

Tom and Brian take the stage in London for a live podcast. With the help of several special guests from the audience, they discuss management of peri-operative therapy in bladder cancer (notably in patients who may refuse cystectomy) and also the emerging pembro plus belzutifan data in adjuvant RCC.

周術期EV+PembroのKEYNOTE-B15試験をはじめとして、大きな話題が多かった今年のASCOGU。結果の解釈から今後の臨床への影響まで語り尽くします。

En este episodio se abordan los resultados más recientes del ensayo fase 3 LITESPARK 011 (belzutifan + lenvatinib frente a cabozantinib). Brian, Tom y Bob Motzer analizan la eficacia, seguridad y las implicaciones de los resultados para la secuenciación de tratamiento.

En esta discusión se exploran los últimos avances en el tratamiento adyuvante del cáncer de riñón, centrándose en los recientes resultados del ensayo fase 3 de belzutifan en combinación con pembrolizumab (LITESPARK-022). Se abordan los pormenores del mecanismo de acción, el desarrollo de biomarcadores y futuras direcciones y líneas de investigación.

En este episodio, Brian, Tom y Matt Galsky analizan los datos del estudio B15 sobre terapia neoadyuvante para el cáncer de vejiga músculo-invasivo cisplatino-elegible, centrándose en la eficacia de EV-Pembro en comparación con cisplatino-gemcitabina. Exploran la SLE, SG y las implicaciones de la duración del tratamiento así como su individualización. La conversación también aborda el papel del ctDNA en las decisiones terapéuticas, las histologías alternativas y la importancia de la terapia sistémica neoadyuvante. El episodio concluye con reflexiones sobre las futuras direcciones en el tratamiento del cáncer de vejiga y la relevancia de los estudios en curso.

La conversación gira en torno al ensayo Sunrise 2, un estudio que investiga la eficacia de TAR-200 combinado con cetrilimab frente a quimiorradioterapia convencional en cáncer de vejiga músculo-invasivo. La discusión aborda el diseño del estudio, la población elegida, los resultados y las implicaciones para futuras estrategias terapéuticas, destacando la importancia de la selección de pacientes y el potencial de TAR-200 en etapas más tempranas del tratamiento.

En este episodio, Evan Yu analiza los datos más recientes sobre cáncer de próstata presentados en ASCO GU, centrándose en los resultados finales de SG del ensayo PEACE-3, las implicaciones del cruce en las curvas de supervivencia y el papel de la terapia con radioligandos e inhibidores de PARP en el tratamiento del cáncer de próstata. 

Brian, Silke and Tom discusses the latest data and insights from ASCO GU 2026 across kidney, prostate, and bladder cancer, highlighting new therapies, trial results, and future directions in urologic oncology.

summaryThis episode explores the latest advances in circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA) in bladder cancer management. Experts discuss how these biomarkers are transforming perioperative decision-making, prognosis, and personalized treatment strategies.

summaryThis detailed discussion covers the latest phase three trial results in kidney cancer, focusing on LITESPARK 011: Belzutifan and Levatnib combination versus Cabozantinib. Brian, Tom and Bob Motzer analyze efficacy, safety, and implications for treatment sequencing.

This in-depth discussion explores the latest advancements in adjuvant kidney cancer treatment, focusing on the recent phase 3 trial results of Belzutifan combined with Pembrolizumab, mechanistic insights, biomarker development, and future research directions.

The conversation revolves around the Sunrise 2 trial, a study investigating the efficacy of TAR-200 combined with cetrilimab versus traditional chemoradiotherapy in muscle-invasive bladder cancer. The discussion covers the study's design, patient population, results, and implications for future treatment strategies, emphasizing the importance of patient selection and the potential for TAR-200 in earlier treatment settings.

In this podcast , Brian, Tom and Matt Galsky discuss the B15 study data on neoadjuvant therapy for muscle invasive bladder cancer, focusing on the efficacy of EV Pembro compared to gem-cis. They explore event-free survival, overall survival, and the implications of treatment duration and individualization. The conversation also touches on the role of ctDNA in treatment decisions, alternative histologies, and the importance of neoadjuvant systemic therapy. The hosts conclude with reflections on future directions in bladder cancer treatment and the significance of ongoing studies.

In this episode, Evan Yu discusses the latest prostate cancer data presented at ASCO GU, focusing on the final overall survival results of the PEACE 3 trial, the implications of crossing survival curves, and the evolving role of radioligand therapy and PARP inhibitors in prostate cancer treatment.

This episode critically examines a recent Nature Medicine paper on the timing of immune therapy infusion in lung cancer, exploring the scientific plausibility, methodological concerns, and implications for future research. Tom, Brian and David McDermott debate the validity of the findings, the review process, and the need for rigorous prospective trials.

SummaryThis Uromigos podcast delves into the evolution and significance of the Prostate Cancer Working Group criteria, highlighting the iterative process of developing guidelines that reflect the latest scientific evidence and clinical practices. The speakers discuss the new PCWG4 including new nomenclature, the role of imaging technologies like PSMA PET, and the importance of biomarkers and patient-reported outcomes in enhancing patient care and treatment efficacy. They emphasize the collaborative nature of the working groups and the ongoing need for adaptation in response to emerging data and technologies.

3人で前立腺癌、腎癌、尿路上皮癌の2025をレビューしました。

In this podcast , the Uromigos discuss the upcoming ASCO GU conference. They delve into the latest research findings, including phase 3 trials, combination therapies, and the significance of biomarkers in treatment. The conversation highlights the importance of belzutifan in kidney cancer and explores the evolving landscape of prostate and bladder cancer treatments. The hosts also share their predictions and insights on how these developments may impact clinical practice.

In this Uromigos podcast episode, Brian and Tom engage with Elaine Chang from the FDA to discuss an analysis of depth of response as an indicator of survival in kidney cancer trials. They explore the FDA's data analysis process, the significance of tumor shrinkage, and the implications of their findings on treatment outcomes. The conversation delves into the limitations of current measurement methods and the potential for using depth of response as an early signal in drug development.

In this episode of the YUromigospodcast, Brian Rini, Tom Powles, and Karine Tawagi discuss the complexities of immunotherapy re-challenge in bladder cancer. They explore the current landscape, including the challenges of existing data, the importance of understanding patient responses, and the potential for future research in antibody-drug conjugates (ADCs). The conversation highlights the need for more definitive studies to guide treatment decisions and improve patient outcomes.

In this podcast, the Brian, Tm and David Einstein discuss the EMBARK study and its implications for patients with biochemically relapsed prostate cancer. They explore the criteria for high-risk patients, the role of PSMA PET imaging, and the findings related to metastasis-free survival and overall survival. The conversation also delves into treatment strategies, adverse events, and patient perspectives on treatment decisions, ultimately highlighting the need for future research in this evolving field.

This podcast discusses the significance of variant histology in urothelial cancer, emphasizing the need for tailored treatment approaches based on histological features. Experts David Aggen, Tom Powles and Brian Rini explore various variant histologies, their implications for treatment, and the challenges in managing mixed histology tumors. The conversation highlights the importance of expert pathology reviews and the evolving landscape of neoadjuvant therapy in this field.

In this podcast, Brian and Tom engage with Pedro Barata to discuss the emerging field of bispecific T cell engagers and antibody-drug conjugates (ADCs) in the treatment of prostate cancer. They explore the promising data surrounding these therapies, the challenges faced in clinical trials, and the implications of phase three studies. The discussion also touches on the comparative development of ADCs in prostate cancer versus bladder cancer, highlighting the unique challenges and opportunities in each area. The conversation concludes with reflections on the future of these therapies and the potential for combination strategies to enhance treatment efficacy

Tom, Brian and Silke discuss the blockbuster 2025 for urothelial cancer

Silke details the 2025 prostate cancer highlights

Brian, Tom and Silke discuss the highlights of RCC for 2025

Matt Galsky joins to discuss the latest iteration of the Uromigos Score in Bladder Cancer. This score quantifies the clinical value of various approaches across several disease states. 30 global experts score each approach.

Michael Morris from MSKCC joins us for an in-depth review of ARPI development across the spectrum of prostate caner

Brian and Tom tag team moderate this session which covers combination data, VEGF/PD1 bispecifics, microbiome approaches, cellular therapy and enrichment strategies.

Tom leads the panel discussion about this evolving space including the RAMPART data and the press release about pembro/belzu.

Brian moderates a panel of Chris Sweeney, Tanya Dorff, Mike Morris, Neeraj Aggarwal and Chuck Ryan as they discus and debate the mHSPC space with many treatment options.

Brian leads a discussion of Rana McCay, Chris Sweeney and Michael Morris on the PSMAddition data and the landscape of radioligands in prostate cancer.

Brian takes the role of the FDA and we conduct a mock ODAC on the CREST and POTOMAC data

Hay vida más allá de EV Pembro. Los Dres Durán, Gómez de Liaño y Coca Membribes repasan el estudio de DV-Toripalimab presentado recientemente en ESMO. Más similitudes que diferencias con EV302 aunque quedan algunas preguntas por responder. Necesitamos más ensayos para entender cuándo hay que interrumpir el tratamiento, así como un mayor seguimiento de los pacientes. También repasaremos el arsenal de nuevos ADCs en marcha que seguirán aportando evidencia en esta población.

Los Dres Duran, Gómez de Liaño y Coca Membribes repasan el escenario perioperatorio en cáncer de vejiga músculo infiltrante. En cisplatino ineldgibles, KN905 es un ensayo transformativo en esta población única que hasta ahora había quedado apartada de los ensayos, y para los que no existía ningún tratamiento efectivo más allá de la cirugía. El rol de ctDNA es clave para entender cuál será el futuro respecto a la cirugía.

IMvigor011試験など最新の臨床データをもとに、ctDNAを用いた周術期治療戦略についての最前線をエキスパートが語ります

ADCが転移性膀胱がん治療にもたらすインパクトをテーマに、RC48-C16試験など最新エビデンスをJun Guo先生をはじめ、世界のエキスパートたちが語ります。

Brian takes the role of FDA and critically appraises the data. Then Tom (CREST) and Jonathan Rosenberg (POTOMAC) defend the data on behalf of each Sponsor. Our expert panel then asks tough questions and votes for or against approval.

Tom moderates Jun Guo, Matt Galsky, Michiel Van der Heidjen and Shilpa Gupta as they discuss this ever-expanding class of agents in bladder cancer.

The first session from UromigosLive 2025! In this episode, Tom moderates as Jonathan Rosenberg, Matt Galsky, Kala Sridhar and Josh Meeks discuss the peri-operative space and the impact of the neoadjuvant EVP and other data.

Tom and Brian discuss the bladder cancer highlights from ESMO 2025. Show throwing is discussed.

Silke, Tom and Brian discuss the prostate and RCC highlights from ESMO 2025

Alex Wyatt joins us to discuss Tom's IMvigor011 data and the field of ctDNA

Matt Galsky discusses the exciting Presidential session data from the Chinese phase 3 of DV+ toripalimab in advanced urothelial cancer.

Scott Tagawa discusses his ESMO Presidential presentation on Lu-PSMA-617 in patients with mHSPC

Elena Castro describes the CAPITELLLO prostate cancer trial and her analysis from ESMO 2025

Paul Nguyen and Chris Sweeney double team the ENZARAD data and put it into context with other data including STAMPEDE

Christof Vulsteke joins Brian and Tom to discuss his practice-changing data on neoadjuvant EVP in MIBC. More applause!!

James Larkin joins to discuss adjuvant durva/treme vs observation in high risk resected RCC

Cristina Rodriguez joins us to discuss her data on front-line triplets, and we also discuss the prospective RNAseq-based biomarker OPTIC study

Brad McGregor joins us on the heels of his #ESMO25 discussion of these important data in the NMIBC landscape.